REG - Barclays PLC - Publication of Pricing Supplement

BarclaysAnnouncement

Yesterday 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250527:nRSa2773Ka&default-theme=true

RNS Number : 2773K  Barclays PLC  27 May 2025

Publication of Pricing Supplement

 

The following pricing supplement (the "Pricing Supplement") is available for
viewing:

 

Pricing Supplement in relation to Barclays PLC's issue of CNY 700,000,000
3.120 per cent. Fixed Rate Senior Callable Notes due 17 May 2030, issued under
the Barclays PLC Debt Issuance Programme.

 

Please read the disclaimer below "Disclaimer - Intended Addressees" before
attempting to access this service, as your right to do so is conditional upon
complying with the requirements set out below.

 

To view the full document, please paste the following URL into the address bar
of your browser.

 

http://www.rns-pdf.londonstockexchange.com/rns/2773K_1-2025-5-27.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/2773K_1-2025-5-27.pdf)

 

A copy of the Pricing Supplement has been submitted to the National Storage
Mechanism and will shortly be available for inspection at:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

For further information, please contact:

 

Barclays Treasury

1 Churchill Place

Canary Wharf

London E14 5HP

 

 

DISCLAIMER - INTENDED ADDRESSEES

 

IMPORTANT: You must read the following before continuing: The following
applies to the Pricing Supplement available by clicking on the link above, and
you are therefore advised to read this carefully before reading, accessing or
making any other use of the Pricing Supplement. In accessing the Pricing
Supplement, you agree to be bound by the following terms and conditions,
including any modifications to them, any time you receive any information from
us as a result of such access.

The Pricing Supplement referred to above must be read in conjunction with the
base prospectus dated 11 March 2025 (as supplemented by the prospectus
supplement dated 1 May 2025) which together constitute a base prospectus (the
"Prospectus") for the purposes of Regulation (EU) 2017/1129, as it forms part
of domestic law of the United Kingdom by virtue of the European Union
(Withdrawal) Act 2018, as amended (the "UK Prospectus Regulation").

 

THE PRICING SUPPLEMENT MAY NOT BE FORWARDED OR DISTRIBUTED OTHER THAN AS
PROVIDED BELOW AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER. THE PRICING
SUPPLEMENT MAY ONLY BE DISTRIBUTED OUTSIDE THE UNITED STATES TO PERSONS THAT
ARE NOT U.S. PERSONS AS DEFINED IN, AND IN RELIANCE ON, REGULATION S UNDER THE
U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). ANY
FORWARDING, DISTRIBUTION OR REPRODUCTION OF THE PRICING SUPPLEMENT IN WHOLE OR
IN PART IS PROHIBITED. FAILURE TO COMPLY WITH THIS NOTICE MAY RESULT IN A
VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS.

 

NOTHING IN THIS ELECTRONIC PUBLICATION CONSTITUTES AN OFFER OF SECURITIES FOR
SALE IN ANY JURISDICTION. ANY NOTES ISSUED OR TO BE ISSUED PURSUANT TO THE
PRICING SUPPLEMENT AND THE PROSPECTUS HAVE NOT BEEN, AND WILL NOT BE,
REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF ANY STATE OF THE
UNITED STATES OR ANY OTHER JURISDICTION. ANY NOTES ISSUED OR TO BE ISSUED
PURSUANT TO THE PRICING SUPPLEMENT AND THE PROSPECTUS MAY NOT BE OFFERED,
SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN AN OFFSHORE TRANSACTION TO A
PERSON THAT IS NOT A U.S. PERSON IN ACCORDANCE WITH RULE 903 OR RULE 904 OF
REGULATION S UNDER THE SECURITIES ACT.

Please note that the information contained in the Pricing Supplement and the
Prospectus referred to above may be addressed to and/or targeted at persons
who are residents of particular countries (specified in the Pricing Supplement
and/or the Prospectus) only and is not intended for use and should not be
relied upon by any person outside these countries and/or to whom the offer
contained in the Pricing Supplement and/or the Prospectus is not
addressed. Prior to relying on the information contained in the Pricing
Supplement and/or the Prospectus you must ascertain from the Pricing
Supplement and the Prospectus whether or not you are part of the intended
addressees of the information contained therein.

Confirmation of your Representation: In order to be eligible to view the
Pricing Supplement or make an investment decision with respect to any Notes
issued or to be issued pursuant to the Pricing Supplement, you must be a
person other than a U.S. person (within the meaning of Regulation S under the
Securities Act). By accessing the Pricing Supplement, you shall be deemed to
have represented that you and any customers you represent are not U.S.
persons, and that you consent to delivery of the Pricing Supplement via
electronic publication.

You are reminded that the Pricing Supplement has been made available to you on
the basis that you are a person into whose possession the Pricing Supplement
may be lawfully delivered in accordance with the laws of the jurisdiction in
which you are located and you may not, nor are you authorised to, deliver the
Pricing Supplement to any other person.

The Pricing Supplement does not constitute, and may not be used in connection
with, an offer or solicitation in any place where offers or solicitations are
not permitted by law. If a jurisdiction requires that the offering be made by
a licensed broker or dealer and the underwriters or any affiliate of the
underwriters is a licensed broker or dealer in that jurisdiction, the offering
shall be deemed to be made by the underwriters or such affiliate on behalf of
Barclays PLC in such jurisdiction. Under no circumstances shall the Pricing
Supplement constitute an offer to sell, or the solicitation of an offer to
buy, nor shall there be any sale of any Notes issued or to be issued pursuant
to the Pricing Supplement, in any jurisdiction in which such offer,
solicitation or sale would be unlawful.

The Pricing Supplement have been made available to you in an electronic form.
You are reminded that documents transmitted via this medium may be altered or
changed during the process of electronic transmission and consequently none of
Barclays PLC, its advisers nor any person who controls any of them nor any
director, officer, employee nor agent of it or affiliate of any such person
accepts any liability or responsibility whatsoever in respect of any
difference between the Pricing Supplement made available to you in electronic
format and the hard copy version available to you as set out in the
Prospectus.

Your right to access this service is conditional upon complying with the above
requirement.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DOCBSGDUCGDDGUR